

INSTITUTE OF BIOMEDICAL RESEARCH CORP.

Unit 1, Masons Press Building

7 Ravenscraig Road, Woodstock 7925

Cape Town, South Africa

+27-82-413-5457

www.m2bio.co

jeff@m2bio.co

Quarterly Report

For the period ending 31 December 2023 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

2,371,424,113 as of December 31, 2023

2,371,424,113 as of September 30, 2023

1,454,642,371 as of March 31, 2023

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐

No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

INSTITUTE OF BIOMEDICAL RESEARCH CORP.

The Company was formerly Neuro-Biotech Corp until March 2014, formerly M45 Mining Resources Inc. until June 2010, and formerly Quantitative Methods Corp. until April 2007.

The public Nevada corporation formed on July 26, 1990; [NV Business ID NV19901030687] ("Surviving Company"), formerly known as Cancean, Inc, merged with the private corporation named Intitule of Biomedical Research Corp. a Nevada corporation formed on June 2, 2021 [NV Business ID: NV20212115346] ("Merging Company"). Due to administrative error, both Companies merged to correct the error on January 5th 2024, effective June 3rd, 2022.

Current State and Date of Incorporation or Registration: NEVADA ACTIVE

Standing in this jurisdiction: (e.g. active, default, inactive): IN GOOD STANDING

Prior Incorporation Information for the issuer and any predecessors during the past five years:

NONE

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

NONE

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

⁴ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Address of the issuer's principal executive office:

1 Masons Press Building, 7 Ravenscraig Road, Woodstock 7925 South Africa

Address of the issuer's principal place of business:

✓ *Check if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: MANHATTAN TRANSFER REGISTRAR CO

Phone: (631) 928 7655

Email: anezaj@mtrco.com

Address: One Grand Central Place, 60 East 42nd Street, Suite 1201, New York, NY 10165

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

NOTE: THE COMPANY HAS INITIATED AN INVESTIGATION INTO SHARES THAT WERE ISSUED IN EXCHANGE FOR DELIVERABLES WHERE THE COMPANY HAS NOT RECEIVED COMMENSURATE VALUE. THE NUMBER OF SHARES IN ISSUE MIGHT BE REDUCED BASED ON THE OUTCOME OF THIS INVESTIGATION.

Trading symbol: MRES

Exact title and class of securities outstanding: COMMON STOCK CLASS A

CUSIP: 45781A107

Par or stated value: \$0.001

Total shares authorized: 5,000,000,000 as of date: 12/31/2023

Total shares outstanding: 2,371,424,113 as of date: 12/31/2023
Number of shareholders 555 as of date: 12/31/2023

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

NONE

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of securities outstanding: PREFERRED STOCK CLASS A
Par or stated value: \$0.001
Total shares authorized: 50,000,000 as of date: 12/31/2023
Total shares outstanding: 8,540,000 as of date: 12/31/2023
Total number of shareholders of record (if applicable): 2 as of date: 12/31/2023

Exact title and class of securities outstanding: PREFERRED STOCK CLASS B
Par or stated value: \$0.001
Total shares authorized: 50,000,000 as of date: 12/31/2023
Total shares outstanding: 35,800,000 as of date: 12/31/2023
Total number of shareholders of record (if applicable): 6 as of date: 12/31/2023

Exact title and class of the security: Series A Warrants
CUSIP (if applicable): _____
Par or stated value: \$0.001
Total warrants authorized: 2,000,000,000 as of date: 12/31/2023
Total warrants outstanding (if applicable): 1,347,635,075 as of date: 12/31/2023
Total number of shareholders of record (if applicable): 31 as of date: 12/31/2023

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

The holders of common stock class A stock are entitled to dividends as declared by the Board of Directors. Each share entitles the holder to one vote. There are no preemption rights.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

The Preferred Stock Class A shares are Control Block shares with no dividend or liquidation rights. The shares are NOT convertible into Common Shares, but each Preferred A share has voting rights equal to ten thousand (10,000) shares of Common Stock. The stock may be returned to Treasury for no consideration.

Each Preferred B share is convertible into Fifty (50) Shares of Common Stock at par at the option of the holder. The holders have equal ratable rights to dividends from funds legally available therefore, when, as and if declared by the Board of Directors and are entitled to share ratably in all of the assets of the Company available for distribution to holders of Preferred stock upon the liquidation, dissolution or winding up of the Corporation. Holders of shares of Preferred stock do not have preemptive or subscription rights.

Holders of shares of Preferred Stock Class B are entitled to 100 votes per share on all matters which shareholders are entitled to vote upon at all meetings of shareholders. The holders of shares of Preferred stock do not have cumulative voting rights, which means that the holders of more than 50% of our outstanding voting securities can elect all the directors of the Company.

3. Describe any other material rights of common or preferred stockholders.

The Series A Warrants entitle the holder to subscribe for one Common share at \$0.005 USD (0.5 cent per share) and shall expire 18 months after issuance. The Company shall have the option to call the warrants by cash exercise provided the Volume Weighted Average Price per share is above \$0.02 USD for a period of ninety days before the Company calls the Warrants. The exercise price shall be payable in cash to the Company at the time of exercise.

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

3) Issuance History

*The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.***

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date 3/31/2021 Common: <u>915,789,038</u> Preferred A: <u>Nil</u> Preferred B: <u>Nil</u> Series A Warrants: <u>Nil</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>06/08/2022</u>	<u>New Issuance</u>	<u>1,000,000,000</u>	<u>Common</u>	<u>N/A</u>	<u>Yes</u>	<u>Kimberly Sue Halvorson</u>	<u>Control Block</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>06/21/2022</u>	<u>New Issuance</u>	<u>8,540,000</u>	<u>Preferred A</u>	<u>\$0.001</u>	<u>No</u>	<u>Kimberly Sue Halvorson</u>	<u>Control Block</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>06/21/2022</u>	<u>New Issuance</u>	<u>1,851,323</u>	<u>Preferred B</u>	<u>\$0.0843</u>	<u>No</u>	<u>Kimberly Sue Halvorson</u>	<u>Debt Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>06/29/2022</u>	<u>New Issuance</u>	<u>45,000,000</u>	<u>Common</u>	<u>N/A</u>	<u>Yes</u>	<u>Ankyro Solutions, Hao Han</u>	<u>Debt Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>09/24/2022</u>	<u>Cancellation</u>	<u>1,000,000,000</u>	<u>Common</u>	<u>N/A</u>	<u>Yes</u>	<u>Kimberly Sue Halvorson</u>	<u>Cancellation</u>	<u>N/A</u>	
<u>08/05/2022</u>	<u>New Issuance</u>	<u>1,500,000</u>	<u>Preferred B</u>	<u>\$0.20</u>	<u>No</u>	<u>Reza Therani Cohen</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>09/30/2022</u>	<u>New issuance</u>	<u>11,050,000</u>	<u>Preferred B</u>	<u>\$0.0157</u>	<u>Yes</u>	<u>Anna Morera Leralta</u>	<u>Management</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>09/30/2022</u>	<u>New issuance</u>	<u>11,050,000</u>	<u>Preferred B</u>	<u>\$0.0157</u>	<u>Yes</u>	<u>Jeff Robinson</u>	<u>Management</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>09/30/2022</u>	<u>New issuance</u>	<u>4,536,177</u>	<u>Preferred B</u>	<u>\$0.0157</u>	<u>Yes</u>	<u>Medigrow Africa Ltd / Mitch Barrett</u>	<u>Service provider</u>	<u>Restricted</u>	<u>4(a)(2)</u>

<u>09/30/2022</u>	<u>New issuance</u>	<u>5,812,500</u>	<u>Preferred B</u>	<u>\$0.001</u>	<u>Yes</u>	<u>Miloreo Venture Group, Inc / Jamie Nelson</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/01/2022</u>	<u>Conversion</u>	<u>48,000,000</u>	<u>Common</u>	<u>\$0.001</u>	<u>Yes</u>	<u>TOH Holdings Inc / Sean Hutchinson</u>	<u>Partial conversion of convertible note</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>Jason Coles</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>50,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>James O'Callaghan</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>Philip Munschauer</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>45,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>Gregg Petrakis</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>5,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>John Hooper</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>25,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>Robert Hooper</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>70,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>Wolters Trust/John Wolters</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>65,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>Ron Hargrove</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>50,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>Michael Ware</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>90,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>Clyde Bianchi</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>10,853,333</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>Robert Keefe</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>15,000,000</u>	<u>Common</u>	<u>\$0.0003</u>	<u>Yes</u>	<u>Jeff Cobb</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Jason Coles</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>50,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>James O'Callaghan</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Philip Munschauer</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>45,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Gregg Petrakis</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>5,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>John Hooper</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>25,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Robert Hooper</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>3/31/2023</u>	<u>New issuance</u>	<u>70,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Wolters Trust/John Wolters</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>

<u>3/31/2023</u>	<u>New issuance</u>	<u>65,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Ron Hargrove</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>3/31/2023</u>	<u>New issuance</u>	<u>50,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Michael Ware</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>3/31/2023</u>	<u>New issuance</u>	<u>90,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Clyde Bianchi</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>3/31/2023</u>	<u>New issuance</u>	<u>10,853,333</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Robert Keefe</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>3/31/2023</u>	<u>New issuance</u>	<u>15,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Jeff Cobb</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>5,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Ron Sorderline</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>20,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Sterling Collins</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>40,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Clyde Bianchi</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>20,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>John Demonico</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>25,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Ron Hargrove</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>50,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Clark Winkler</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>30,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>John H. Wolters and Tamaara K. Wolters Trust / John Wolters</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>5,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Ron Sorderline</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>20,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Sterling Collins</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>40,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Clyde Bianchi</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>20,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>John Demonico</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>25,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Ron Hargrove</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>50,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Clark Winkler</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/2/2023</u>	<u>New issuance</u>	<u>30,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>John H. Wolters and Tamaara K. Wolters Trust / John Wolters</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>49,291,210</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Lee & Lee, Inc / Shannon Stefanik</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)

<u>6/30/2023</u>	<u>New issuance</u>	<u>21,968,408</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Chris Broussard</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Olivia Demonico</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>50,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>John Demonico</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Sofia Demonico</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>16,666,666</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Paige E Winkler</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>16,666,666</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Regan E Winkler</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Luke Kenny</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>17,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Michael Bean</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>William Allen Fadaol</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>20,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Eugenia Garcia</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>8,333,333</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Justin James Gilbert</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Gregg Petrakis</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>100,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Clyde Bianchi</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Robert Hooper</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>8,333,334</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Dennis Bater</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Michael Ware</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Robert Keefe</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Ron Hargrove</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>50,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Jeffrey Krueger</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>49,291,210</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Lee & Lee, Inc / Shannon Stefanik</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>21,968,408</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Chris Broussard</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Olivia Demonico</u>	<u>Private Placement</u>	<u>Restricted</u>	506(b)

<u>6/30/2023</u>	<u>New issuance</u>	<u>50,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>John Demonico</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Sofia Demonico</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>16,666,666</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Paige E Winkler</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>16,666,666</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Regan E Winkler</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Luke Kenny</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>17,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Michael Bean</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>William Allen Fadaol</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>20,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Eugenia Garcia</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>8,333,333</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Justin James Gilbert</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Gregg Petrakis</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>100,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Clyde Bianchi</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Robert Hooper</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>8,333,334</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Dennis Bater</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Michael Ware</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Robert Keefe</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Ron Hargrove</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>6/30/2023</u>	<u>New issuance</u>	<u>50,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Jeffrey Krueger</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>7/13/2023</u>	<u>Conversion</u>	<u>15,000,000</u>	<u>Common</u>	<u>0.001</u>	<u>Yes</u>	<u>TOH Holdings Inc / Sean Hutchinson</u>	<u>Partial conversion of convertible note</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Ryan List</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>80,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Sterling Collins</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Clyde Bianchi</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>John Demonico</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>

<u>8/7/2023</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Ron Hargrove</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>20,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Eugenia Garcia</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>5,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Larry Topper</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>37,767,358</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Jim O'Callagahn</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>754,767</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>Christopher Charles Broussard</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Ryan List</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>80,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Sterling Collins</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>10,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Clyde Bianchi</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>John Demonico</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Ron Hargrove</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>20,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Eugenia Garcia</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>5,000,000</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Larry Topper</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>37,767,358</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Jim O'Callagahn</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
<u>8/7/2023</u>	<u>New Issuance</u>	<u>754,767</u>	<u>Series A Warrant</u>	<u>Nil</u>	<u>Yes</u>	<u>Christopher Charles Broussard</u>	<u>Private Placement</u>	<u>Restricted</u>	<u>506(b)</u>
Shares Outstanding on Date of This Report:									
<u>Ending Balance:</u>									
Date <u>12/31/2023</u>	Common: <u>2,371,424,113</u>								
	Class A Preferred: <u>8,540,000</u>								
	Class B Preferred: <u>35,800,000</u>								
	Series A Warrants: <u>1,347,635,075</u>								

Example: A company with a fiscal year end of December 31st 2023, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2022 through December 31, 2023 pursuant to the tabular format above.

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities :

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *** You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
<u>4/01/2023</u>	<u>100,000</u>	<u>92,860</u>	<u>7,140</u>	<u>6/30/2023</u>	<u>At par .001</u>	<u>Seed Trust. Control person: Murray Lynton-Edwards</u>	<u>Working capital loan converted to debt</u>

*****Control persons for any entities in the table above must be disclosed in the table or in a footnote here.**

Use the space below to provide any additional details, including footnotes to the table above:

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Institute of Biomedical Research Corp., trading as M2Bio Sciences, is a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research. M2Bio's mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies.

M2Bio conducts research at the M2Bio Discovery Centre for AI-Driven Phytomedicine Research at the University of Pretoria in South Africa. The research is aimed at providing scientific backing for the Company's expanding product range – including plant-based medicines.

B. List any subsidiaries, parent company, or affiliated companies.

M2Bio Sciences Food and Beverage (Pty) Ltd

Neurai Life Sciences (Pty) Ltd

Tsime Pharmaceuticals and Medical Supplies (Pty) Ltd

MJMedTech, Inc.

C. Describe the issuers' principal products or services.

The company, through its subsidiaries, owns and operates three cannabis consumer goods brands Medspresso™, Dr. AnnaRx™, and Liviana™. The brands span across a wide range of premium CBD- and mushroom-infused consumer goods including bioceuticals, health and wellness, and precision foods and beverages. With operations currently based in Cape Town, South Africa the company and its brands are positioned in the high-value market segment. In order to position itself within the high-value market segment, M2Bio has had to consistently focus on producing and sourcing the highest-quality ingredients available in the market, from pharmaceutical-grade CBD extract to premium coffees and extra virgin olive oils.

In March 2023 the Company signed a distribution agreement with Innovative Holdings Alliance Inc. to distribute the Company's products in the United States of America. The Company's products are well suited to the premium markets in the USA.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

Operational Rental: Unit 01, Mason's Press, 7 Ravenscraig Road, Woodstock, 7925, Cape Town, South Africa, measuring 775 square foot.

Operational Rental: Floor 1, 31 Harbour Road, Hout Bay, 7806, Cape Town, South Africa, measuring 3,624 square foot.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>Drasko Pekovic</u>	<u>Shareholder</u>	<u>Montreal, Canada</u>	<u>450,000,000</u>	<u>Common Class A</u>	<u>19.0%</u>	_____
<u>Jeff Robinson</u>	<u>President, Director and CEO</u>	<u>Cape Town, South Africa</u>	<u>4,270,000</u>	<u>Preferred A</u>	<u>50.0%</u>	
<u>Anna Morera Leralta</u>	<u>Secretary and Chief Medical Officer</u>	<u>Barcelona, Spain</u>	<u>4,270,000</u>	<u>Preferred A</u>	<u>50.0%</u>	_____
<u>Kim Halvorson</u>	<u>Shareholder</u>	<u>Marysville WA</u>	<u>1,851,323</u>	<u>Preferred B</u>	<u>5.2%</u>	
<u>Anna Morera Leralta</u>	<u>Secretary and Chief Medical Officer</u>	<u>Barcelona, Spain</u>	<u>11,050,000</u>	<u>Preferred B</u>	<u>30.9%</u>	_____
<u>Jeff Robinson</u>	<u>President and CEO</u>	<u>Cape Town, South Africa</u>	<u>11,050,000</u>	<u>Preferred B</u>	<u>30.9%</u>	
<u>Medigrow Africa Limited</u>	<u>Shareholder</u>	<u>British Virgin Islands</u>	<u>4,536,177</u>	<u>Preferred B</u>	<u>12.7%</u>	Mitch Barrett
<u>Miloreo Venture Group, Inc</u>	<u>Shareholder</u>	<u>Cayman Islands</u>	<u>5,812,500</u>	<u>Preferred B</u>	<u>16.2%</u>	Jamie Nelson
<u>Willem Jonker</u>	<u>CFO and Director</u>	<u>Cape Town, South Africa</u>	<u>Nil</u>			
<u>Clyde Bianchi</u>	<u>Shareholder</u>	<u>Bergen, NY</u>	<u>240,000,000</u>	<u>Common</u>	<u>10.1%</u>	
<u>Ron Hargrove</u>	<u>Shareholder</u>	<u>Bellmore, NY</u>	<u>150,000,000</u>	<u>Common</u>	<u>6.3%</u>	
<u>John Demonico</u>	<u>Shareholder</u>	<u>Greenville, SC</u>	<u>120,000,000</u>	<u>Common</u>	<u>5.1%</u>	

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

- A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

* Note: The answers below relate to officers of the Company, as the management of the Company cannot respond in respect of shareholders that are unrelated to them.

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

NONE

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

NONE

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

NONE

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

NONE

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

Ms. Kim Halvorson (shareholder) is prohibited as a service provider by OTCMarkets.

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

NONE

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NONE

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: McMurdo Law Group, LLC
Address 1: 1185 Avenue of the Americas, 3rd Floor
Address 2: New York, NY 10036
Phone: 917.318.2865
Email: matt@nannaronelaw.com

Accountant or Auditor

Name: NONE
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations

Name: NONE
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): <https://twitter.com/m2bio>
Discord: _____
LinkedIn: <https://www.linkedin.com/company/m2bio/>
Facebook: <https://www.facebook.com/M2BIO/>
Instagram: <https://www.instagram.com/m2bio.sciences/> _____
YouTube: <https://www.youtube.com/channel/UCOir-dW7tmY7RGKXIUI5esQ>
TikTok: <https://www.tiktok.com/@m2bio.sciences>
Reddit: <https://www.reddit.com/user/M2Bio-Sciences/>
Linked Tree: <https://linktr.ee/m2biosciences>

M2Biome Division:

Website Link <https://m2biome.com/>
info@m2biome.health m2biome@m2bio.co
Instagram <https://www.instagram.com/m2biome/>
Facebook <https://www.facebook.com/M2Biome/>
Twitter <https://twitter.com/M2Biome>
Pinterest m2biome@m2bio.co
Youtube www.youtube.com/@M2Biome-vw2lo

Medspresso:

Website link <https://medspresso.co/>
Twitter <https://twitter.com/Medspresso>
Instagram <https://www.instagram.com/medspresso.official/>
TikTok <https://www.tiktok.com/@medspresso>
LinkedIn Company Page <https://www.linkedin.com/company/medspresso%E2%84%A2/>
LinkedIn Group [Medspresso - Group](#)
Facebook Page <https://www.facebook.com/Medspresso/>
Facebook Group [Medspresso - Group](#)
YouTube <http://www.youtube.com/@medspresso52>
Pinterest <https://www.pinterest.co.uk/Medspresso/>
Linked Tree <https://linktr.ee/Medspresso>

Liviana:

Website Link <https://liviana.co.za/>
Twitter <https://twitter.com/livianaoliveoil>
Instagram <https://www.instagram.com/liviana.health/>
LinkedIn Company Page <https://www.linkedin.com/company/liviana-health/>
Facebook Page <https://www.facebook.com/liviana.health/>
Facebook Group [Olive Oil Health, Science and Recipes](#)
Pinterest <https://www.pinterest.co.uk/Livianahealth/>

TikTok <https://www.tiktok.com/@liviana.health>
info@liviana.co.za info@liviana.co.za
Linked Tree linktr.ee/liviana.health

M2Sentient

Website Link <https://m2sentient.com/>
Instagram <https://www.instagram.com/m2sentient/>
Facebook <https://www.facebook.com/M2Sentient>
LinkedIn <https://www.linkedin.com/company/m2sentient/>
Twitter <https://twitter.com/M2Sentient>

M2Enviro

Website Link <https://m2enviro.com/>
Instagram <https://www.instagram.com/m2enviro/>
Facebook <https://www.facebook.com/m2enviro>
Twitter <https://twitter.com/M2Envirolabs>
Tiktok <https://www.tiktok.com/@m2enviro>
LinkedIn <https://www.linkedin.com/company/m2enviro/>
Linked tree linktr.ee/m2enviro

M2MMA

Website Link <https://m2mma.com/>
Twitter <https://twitter.com/M2MMAofficial>
Instagram <https://www.instagram.com/m2mmaofficial/>
Facebook <https://www.facebook.com/m2mmaofficial>
YouTube https://www.youtube.com/@M2MMA_Official
TikTok <https://www.tiktok.com/@m2mmaofficial>

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: NONE
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Willem Jonker
Title: Chief Financial Officer
Relationship to Issuer: Chief Financial Officer

B. The following financial statements were prepared in accordance with:

☐ IFRS
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Willem Jonker
Title: Chief Financial Officer
Relationship to Issuer: Chief Financial Officer

Describe the qualifications of the person or persons who prepared the financial statements: Chartered Accountant (South Africa)

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Jeff Robinson certify that:

1. I have reviewed this Disclosure Statement for Institute of Biomedical Research Corp;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

February 14, 2024

/s/ Jeff Robinson [CEO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

Principal Financial Officer:

I, Willem Jonker certify that:

1. I have reviewed this Disclosure Statement for Institute of Biomedical Research Corp;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

February 14, 2024

/s/ Willem Jonker [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

INSTITUTE OF BIOMEDICAL RESEARCH CORP.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	December 31, 2023		September 30, 2023
<u>ASSETS</u>			
Current assets:			
Cash	\$ 4,377		\$ 45,123
Accounts Receivable	\$ 44,622		\$ 61,093
Inventories	\$ 46,008		\$ 41,080
Prepaid expenses	144,947		\$ 148,538
Total Current Assets	239,954		\$ 295,834
Fixed Assets	\$ 12,689		\$ 11,719
Prepaid expenses	\$ 75,853		\$ 108,139
Listed Equities	\$ 165,000		\$ 60,000
Licence	\$ 16,567		\$ 17,580
Total Assets	\$ 510,063		\$ 493,272
<u>LIABILITIES AND STOCKHOLDERS' DEFICIT</u>			
Current liabilities:			
Current Liabilities	\$ 492,736		\$ 271,642
Long Term Liabilities	\$ 100,000		\$ 668,150
Total Liabilities	\$ 592,736		\$ 939,792
Shareholder Equity			
Common Stock, \$0.001 par value; 5,000,000,000 shares authorized, 2,371,424,113 shares issued and outstanding	\$ 2,371,424		\$ 2,371,424
Preferred A Stock, \$0.001 par value; 50,000,000 shares authorized, 8,540,000 shares issued and outstanding	\$ 854		\$ 854
Preferred B Stock, \$0.001 par value; 100,000,000 shares authorized, 35,800,000 shares issued and outstanding	\$ 35,800		\$ 35,800
Additional paid in capital	\$ 56,739,283		\$ 56,739,283
Accumulated deficit	-59,230,035		\$ -59,593,882
Total Stockholders' deficit	\$ -82,674		\$ -446,520
Total Liabilities and Stockholders' deficit	\$ 510,063		\$ 493,272

INSTITUTE OF BIOMEDICAL RESEARCH CORP.
STATEMENTS OF OPERATIONS
(Unaudited)

	For the Quarter Ended	
	December 31,	September 30
	<u>2023</u>	<u>2023</u>
Sales	\$ 14,466	\$ 3,799
Cost of Sales	11,453	2,944
Gross Profit	\$ 3,013	\$ 855
Interest income	\$ 518	\$ 1,163
Other income	\$ 509,050	\$ 9,000
Fair Value Adjustment	\$ 105,000	\$ -41,250
Profit/Loss on currency translation	\$ 58,973	\$ 374
	\$ 676,554	\$ -29,858
Operating expenses:		
Interest Expense	\$ -	\$ 16,102
Research Costs	\$ 134,516	\$ 2,485
Sales and advertising	\$ 2,382	\$ 2,333
General and administrative expenses	\$ 175,810	\$ 183,865
Total operating expenses	\$ 312,707	\$ 204,786
Profit/(Loss) from operations	\$ 363,847	\$ -234,644
Provision for income tax	—	—
Net Profit/(Loss)	\$ 363,847	\$ -234,644

STATEMENTS OF STOCKHOLDERS' DEFICIT
FOR THE QUARTER ENDED DECEMBER 31, 2023 and SEPTEMBER 30, 2023
(Unaudited)

	Common Stock		Preferred A Stock		Preferred B Stock		Additional Paid in Capital	Accumulated Deficit	Total
	Shares	Amount	Shares	Amount	Shares	Amount			
Balance on July 1, 2023	2,092,901,988	2,092,902	8,540,000	854	35,800,000	35,800	56,934,249	-59,359,237	-295,431
Net change	278,522,125	278,522	-	-	-	-	-194,966	-234,645	-151,088
Balance on September 30, 2023	2,371,424,113	2,371,424	8,540,000	854	35,800,000	35,800	56,739,283	-59,593,882	-446,520
	Common Stock		Preferred A Stock		Preferred B Stock		Additional Paid in Capital	Accumulated Deficit	Total
	Shares	Amount	Shares	Amount	Shares	Amount			
Balance on October 1, 2023	2,371,424,113	2,371,424	8,540,000	854	35,800,000	35,800	56,739,283	-59,593,882	-446,520
Net change	0	-	-	-	-	-	0	363,847	363,847
Balance on December 31, 2023	2,371,424,113	2,371,424	8,540,000	854	35,800,000	35,800	56,739,283	-59,230,035	-82,673

See the accompanying notes to these unaudited financial statements.

INSTITUTE OF BIOMEDICAL RESEARCH CORP.
STATEMENTS OF CASHFLOWS
(Unaudited)

	For the Quarter Ended			
		December 31,		September 30,
		2023		2023
Cash flows from operating activities:				
Net Profit / (Loss)	\$	363,847	\$	-234,644
Non-cash items (net)		0		-4671
Changes in Assets and Liabilities:		-404,592	\$	144,038
Net Cash generated by/(used in) Operating Activities		-40,746		-158,139
-				
Net Cash from Financing Activities		0	\$	151,088
Net increase / (decrease) in cash		-40,746	\$	-7,051
Cash – beginning of period		45,123	\$	52,174
Cash – end of period	\$	4,377	\$	45,123

See the accompanying notes to these unaudited financial statements.

INSTITUTE OF BIOMEDICAL RESEARCH CORP.

Notes to the Unaudited Financial Statements

December 31, 2023

NOTE 1 - BUSINESS

INSTITUTE OF BIOMEDICAL RESEARCH Corp. (the “Company”) was incorporated under the laws of the State of Nevada on July 26, 1990.

The Company is trading as M2Bio Sciences. M2Bio Sciences is a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research. M2Bio’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies.

M2Bio conducts research at the M2Bio Discovery Centre for AI-Driven Phytomedicine Research at the University of Pretoria in South Africa. The research is aimed at providing scientific backing for the Company’s expanding product range – including plant-based medicines.

The company, through its subsidiaries, owns and operates three cannabis consumer goods brands Medspresso™, Dr. AnnaRx™, and Liviana™. The brands span across a wide range of premium CBD- and mushroom-infused consumer goods including bioceuticals, health and wellness, and precision foods and beverages. With operations currently based in Cape Town, South Africa the company and its brands are positioned in the high-value market segment. In order to position itself within the high-value market segment, M2Bio has had to consistently focus on producing and sourcing the highest-quality ingredients available in the market, from pharmaceutical-grade CBD extract to premium coffees and extra virgin olive oils.

In March 2023 the Company signed a distribution agreement with Innovative Holdings Alliance Inc. to distribute the Company’s products in the United States of America. The Company’s products are well suited to the premium markets in the USA.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The Company’s unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

These Financial Statements are prepared on the basis of information provided by the Management of the Company, and the Management is responsible for the completeness and materiality of these financial statements.

Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent

assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

Concentration of Credit Risk

The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements.

Revenue Recognition

The Company recognizes revenue when there is persuasive evidence of an arrangement, delivery has occurred, the selling price is determinable, collectability is reasonably assured and there are no significant remaining performance obligations.

Employment Agreements

The Group employs 24 staff as at December 31, 2023.

Income Taxes

Income taxes are accounted for under the assets and liability method. Current income taxes are provided in accordance with the laws of the respective taxing authorities. Deferred income taxes are provided for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized.

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As of December 31, 2023, the Company's revenue is insufficient to cover its operating expenses. The company has \$510,063 in Assets and an accumulated deficit of \$59,230,035. The Company's ability to raise additional capital through the future issuances of common stock and/or debt financing is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

NOTE 4 – OTHER ITEMS

- i. Legal Proceedings – None.
- ii. The company has substantial net operating loss carry forwards for federal income tax purposes estimated at about \$59,230,035. Due to the company's issuance of stock, the company's use of its existing loss carry-forwards may be restricted under Section 382 of the Internal Revenue Code.

NOTE 5 – LOANS PAYABLE

As of December 31, 2023, the Company owes \$100,000 (\$668,150 as at September 30, 2023) from the issue of convertible notes with a face value of \$92,860 at 10% interest per annum, convertible into common shares of the Company's common stock at \$0.001.

NOTE 6 – RELATED PARTY TRANSACTIONS

M2Bio Sciences Food and Beverage (Pty) Ltd, a subsidiary, rents premises in Hout Bay, South Africa, at market related rates from a company of which Mr. Willem Jonker (Director and CFO) is a director.

NOTE 7 - SUBSEQUENT EVENTS

On January 21, 2024, the Company sold 100% ownership of the concept, business model, contacts and contracts that collectively can be used to establish a mixed martial arts league to Real American Capital Corporation (Symbol: RLAB) in exchange for a controlling interest in RLAB.

Other than the above, Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the Balance Sheet date through the date the Financial Statements were issued, and has determined that no material subsequent events exist.